VolitionRx Limited announces financial results and a business update for the second quarter ended June 30, 2025.
The company is focused on commercializing its Nu.Q ® platform in the human diagnostics market and is in confidential discussions with more than ten companies.
Volition aims to secure multiple licensing agreements in the human diagnostics space this year, following a successful strategy in the veterinary market.
Financial Highlights
Recorded just over $0.4 million revenue for the second quarter, with 15% growth over the prior year. Net loss down 11% for the quarter and 24% for the first half compared to prior year. Net cash used in operating activities down 30% over the same period last year.
Cash and Equivalents
As of June 30, 2025, cash and cash equivalents totaled approximately $2.3 million compared to $3.3 million at the end of 2024. Received $1.2 million from a registered direct offering after the quarter end.
Upcoming Milestones
Expect the first human out licensing deal this quarter. Making strong progress with diverse deal structures expected.
- Volition is making significant progress in commercializing its Nu.Q ® platform in the human diagnostics market.
- The company's financial performance for the second quarter reflects growth in revenue and a decrease in net loss compared to the prior year.
- The received funding from a registered direct offering demonstrates investor confidence in Volition's future prospects.
VolitionRx Limited is poised for continued growth and success as it focuses on licensing agreements in the human diagnostics space. The company's innovative approach to early disease detection positions it well for future developments and partnerships.